Search This Blog

Friday, June 20, 2025

Genentech Combo Prolongs Remission for Relapsed or Refractory Large B-cell Lymphoma

 – Pivotal Phase III SUNMO study demonstrated an 11.5 month median progression-free survival – three times longer than R-GemOx –

– This well-tolerated investigational combination therapy avoids traditional chemotherapy and may be suitable for outpatient community care –

– Results will be submitted to global health authorities including the U.S. Food and Drug Administration –

https://finance.yahoo.com/news/genentech-lunsumio-polivy-combination-significantly-154500744.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.